Fluarix, inactivated split-virus influenza vaccine (Q36407258)

14 August 2017

1 reference

title

Fluarix, inactivated split-virus influenza vaccine (English)

1 reference

14 August 2017

0 references

Rose GW

1

1 reference

PubMed ID

16503738

14 August 2017

Cooper CL

series ordinal

2

1 reference

PubMed ID

16503738

14 August 2017

language of work or name

English

0 references

publication date

1 March 2006

1 reference

Expert Opinion on Biological Therapy

14 August 2017

1 reference

14 August 2017

6

1 reference

14 August 2017

3

1 reference

14 August 2017

301-310

1 reference

Impact of influenza epidemics on mortality in the United States from October 1972 to May 1985.

14 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.301

The impact of influenza epidemics on mortality: introducing a severity index.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.301

Mortality associated with influenza and respiratory syncytial virus in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.301

The impact of influenza epidemics on hospitalizations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.301

Influenza-associated hospitalizations in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.301

Reducing the impact of viral respiratory infections in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.301

Comparison of immunogenicity and tolerability of a virosome-adjuvanted and a split influenza vaccine in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.301

Functional balance between haemagglutinin and neuraminidase in influenza virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.301

Reassortment and evolution of current human influenza A and B viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.301

Influenza vaccines. A reappraisal of their use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.301

The annual production cycle for influenza vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.301

Live cold-adapted influenza A vaccine produced in Vero cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.301

Development of cell culture (MDCK) live cold-adapted (CA) attenuated influenza vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.301

Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.301

Antibody response to influenza vaccination in splenectomized patients in Poland.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.301

Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.301

Methodological quality of studies and patient age as major sources of variation in efficacy estimates of influenza vaccination in healthy adults: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.301

Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.301

The immunogenicity of influenza virus vaccine in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.301

Immune response to influenza vaccination in children and adults with asthma: effect of corticosteroid therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.301

A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.301

Evaluation of a Two-Dose Regimen of Influenza A/New Jersey/76 Subunit Virus Vaccine in Three- to IO-Year-Old Children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.301

Current issues with influenza vaccination in egg allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.301

The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.301

Safety and immunogenicity of influenza vaccination in individuals infected with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.301

Influenza vaccination in liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.301

Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.301

Influenza vaccine in healthy children: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.3.301

21 January 2018

Identifiers

DOI

10.1517/14712598.6.3.301

1 reference

14 August 2017

1 reference

PubMed ID

16503738